XORTX Therapeutics Inc. (XRTX), Wednesday announced that it has received responses from the US Food and Drug Administration regarding new drug application process for XORLO, a proprietary formulation of oxypurinol to treat individuals suffering from gout.
During the Type B meeting, the agency reviewed chemistry, manufacturing, pharmacology, toxicology and clinical evidence related to the company's XRx-026 program.
Upon receiving FDA's response, the company will now proceed to finalize meeting minutes with the agency, prepare and file an Investigative New Drug application for the XRx-026 program, characterize pharmacokinetics of XORLO, manufacture and validate commercial drug supplies, and prepare and file a NDA.
The company expects to file NDA in the first half of 2026.
In the pre-market hours, XORTX's stock is trading at $1.01, down 1.46 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.